Business Context and Reporting Period
Company: Bioanalytical Systems, Inc. (Note: Input metadata referenced "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: The Company provides contract laboratory research services (bioanalytical analysis, toxicology) and manufactures scientific instruments for pharmaceutical development. Operations are divided into Services and Products segments. The Company exited the Phase I clinical study market following the sale of its Baltimore Clinical Pharmacology Research Unit (CPRU) in June 2008.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2009 | Nine Months Ended June 30, 2009 |
|---|---|---|
| Total Revenue | $8,121 | $23,264 |
| Gross Profit | $2,135 | $5,054 |
| Operating Income (Loss) | $(571) | $(4,344) |
| Net Loss (Continuing Ops) | $(632) | $(4,047) |
| Net Loss (Total) | $(632) | $(4,047) |
| Cash and Cash Equivalents | $222 (as of June 30, 2009) | N/A |
| Net Cash from Operating Activities | N/A | $1,216 |
| Total Debt (Current + Long-term) | $10,325 | N/A |
Note: Total Debt calculated as Revolving line of credit ($1,491) + Current portion of capital lease ($698) + Current portion of long-term debt ($516) + Capital lease obligation ($931) + Long-term debt ($8,324).
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 29.1% year-over-year for the quarter and 28.0% for the nine-month period. This was driven by a 32.6% drop in Service revenue (due to study delays and reduced bookings) and a 15.6% drop in Product revenue.
- Margin Compression: Gross margin for the nine months ended June 30, 2009, was 21.7%, down significantly from 38.3% in the prior year. Cost of service revenue as a percentage of revenue increased to 90.6% due to fixed costs remaining high while sales volume dropped.
- Impairment Loss: The Company recorded a non-cash impairment loss of $472,000 related to goodwill at its UK facility, which had been experiencing operating losses.
- Operating Loss: The Company reported an operating loss of $4.3 million for the nine months ended June 30, 2009, compared to operating income of $3.5 million in the same period of the prior year.
Guidance, Outlook, and Risks
- Market Conditions: Management cites the global economic recession as the primary driver for delayed study initiations and reduced spending by pharmaceutical clients. However, new study initiations increased in the third quarter of fiscal 2009.
- Liquidity and Covenants: The Company has been in breach of fixed charge coverage and tangible net worth covenants with its lenders (Regions Bank and National City Bank). Waivers and amendments were obtained in February and May 2009, and a Fourth Amendment was executed on July 17, 2009, to extend waivers through the third fiscal quarter. Borrowing capacity is limited to a "borrowing base" of $3,000,000.
- Cost Reductions: The Company implemented a workforce reduction in January 2009 (approx. 12% reduction in annual compensation) and a 43% reduction in the CEO's base salary. Capital expenditures have been frozen for "unnecessary" items.
- Change of Control Risk: On July 29, 2009, shareholders demanded a special meeting to nominate new directors. This action constitutes a "change of control" under the Company's loan agreement, potentially triggering a default if not resolved.
- Internal Controls: A material weakness in internal controls regarding income tax accounting was identified in the prior fiscal year. Management concluded that disclosure controls and procedures were effective as of June 30, 2009.
Investor Verification Checklist
- Covenant Compliance: Verify the status of the July 2009 loan amendments and whether the Company remains in compliance with the amended fixed charge coverage and tangible net worth ratios.
- Change of Control Status: Confirm the outcome of the shareholder demand for a special meeting and whether it has triggered a default under the National City Bank credit agreement.
- UK Facility Viability: Assess the turnaround plan for the UK facility, which resulted in a full goodwill impairment and continues to generate operating losses.
- Revenue Recovery: Monitor the trend of new bookings and study initiations to determine if the Q3 revenue increase is sustainable or a temporary fluctuation.
- Contingent Liabilities: Review the $800,000 annual contingent liability related to the lease of the sold CPRU facility, which remains in effect through 2015 if the buyer defaults.